{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE294nnn/GSE294635/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294635"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"RNA profiling of wild-type Osteosarcoma (U2OS) cells and its KO derivative (PERK KO) upon Palbociclib treatment for 4 days","description":"Dysregulation of cyclin-dependent kinase 4/6 (CDK4/6) occurs in various cancers. Three CDK4/6 inhibitors are approved for clinical use including Palbociclib (PD). CDK4/6 inhibitors trigger early G1 cell cycle arrest in cells, leading to cellular quiescence while long term inhibition enforces transition to senescence. PERK is a shared Kinase between the Unfolded Protein Response (UPR) and the Integrated Stress Response (ISR). We report that PERK inhibition accelerate Palbociclib induce senescence.","dates":{"publication":"2026/04/30"},"accession":"GSE294635","cross_references":{"GSM":["GSM8913061","GSM8913066","GSM8913067","GSM8913068","GSM8913069","GSM8913062","GSM8913063","GSM8913064","GSM8913065"],"GPL":["34284"],"GSE":["294635"],"taxon":["Homo sapiens"]}}